secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001193125-22-216147
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q2 net loss $61.2M; advances first two RAS(ON) inhibitors into clinic
--------------------------------------------------------------------------------

- Net loss $61.2M in Q2 2022 vs $44.3M in Q2 2021; revenue from Sanofi collab $9.1M.
- Cash, equivalents and securities $461.4M at June 30, 2022; July public offering raised $264.5M gross.
- Updated FY 2022 GAAP net loss guidance to $260-280M; stock-based comp $30-35M.
- First patient dosed in Phase 1/1b trial of RAS(ON) inhibitor RMC-6236; site activation for RMC-6291 underway.
- Appointed Lorence Kim (ex-Moderna, Goldman Sachs) and Sushil Patel (ex-Genentech) to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522216147/0001193125-22-216147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522216147/d348230d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-216147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer